Page 48 - 《中国药房》2026年1期
P. 48

米托蒽醌脂质体对卵巢癌细胞增殖、迁移及干性的影响
                                                                                               Δ


                                    2
                                            3 #
                            3
          王 冬    1, 2* ,张 悦 ,储百旺 ,孙 华 (1.天津医科大学肿瘤医院药学部/国家恶性肿瘤临床医学研究中心/天
          津市肿瘤防治重点实验室/天津市恶性肿瘤临床医学研究中心,天津 300060;2.天津市肿瘤医院空港医院药学
          部,天津 300308;3.天津科技大学生物工程学院,天津 300457)


          中图分类号  R965      文献标志码  A      文章编号  1001-0408(2026)01-0042-07
          DOI  10.6039/j.issn.1001-0408.2026.01.08


          摘   要  目的  探讨米托蒽醌脂质体(Lipo-MIT)对卵巢癌细胞增殖、迁移及癌症干细胞(CSCs)干性的影响,并基于磷脂酰肌醇3
          激酶(PI3K)/蛋白激酶B(AKT)通路探讨其作用机制。方法  通过体外实验考察Lipo-MIT对细胞增殖、迁移和CSCs干性特征的影
          响。构建裸鼠人卵巢癌细胞A2780异种移植瘤模型,探究2、5 mg/kg Lipo-MIT对荷瘤裸鼠安全性以及体内肿瘤生长、肿瘤组织病
          理特征的影响,并考察 Lipo-MIT 对细胞与肿瘤组织中 PI3K/AKT 通路、上皮-间充质转化、干性相关蛋白表达的调控作用。结果
          Lipo-MIT 对 A2780、SK-OV3 和 OV-CAR5 细胞的半数抑制浓度分别为 0.72、5.41、2.77 μmol/L;与溶剂对照(0.1% 二甲基亚砜)比
          较,0.5~2.5 μmol/L Lipo-MIT可显著降低细胞克隆形成率、缩短细胞迁移距离、减少迁移细胞数、下调神经钙黏素(N-cadherin)蛋
          白表达、上调上皮钙黏素(E-cadherin)蛋白表达(P<0.05),并降低肿瘤球形成率、下调乙醛脱氢酶1A1(ALDH1A1)蛋白表达(P<
          0.05);1.0、2.5 μmol/L Lipo-MIT 可显著降低干细胞成球概率和下调细胞中性别决定区 Y 框蛋白 2 表达(P<0.05)。2、5 mg/kg
          Lipo-MIT对荷瘤裸鼠的体重、饮食量和饮水量及脏器(心、肝、脾、肺、肾)指数均无明显影响(P>0.05),可显著改善肿瘤组织的病
          理变化,并可显著抑制肿瘤组织中N-cadherin和CD133、ALDH1A1(仅5 mg/kg Lipo-MIT)蛋白表达(P<0.05),上调E-cadherin(仅
          5 mg/kg Lipo-MIT)蛋白表达(P<0.05)。不同浓度/剂量Lipo-MIT均可显著降低细胞/肿瘤组织中PI3K、AKT蛋白的磷酸化水平
         (P<0.05)。结论  Lipo-MIT可通过抑制PI3K/AKT通路活性来抑制卵巢癌细胞的增殖、迁移和干性。
          关键词  米托蒽醌脂质体;卵巢癌;癌症干细胞;PI3K/AKT通路


          Effects of Mitoxantrone liposomes on the proliferation, migration and stemness in ovarian cancer cells
          WANG Dong ,ZHANG Yue ,CHU Baiwang ,SUN Hua(1.  Dept.  of  Pharmacy,  Tianjin  Medical  University
                                                    2
                                     3
                      1, 2
                                                              3
          Cancer  Institute  &  Hospital/National  Clinical  Research  Center  for  Cancer/Tianjin  Key  Laboratory  of  Cancer
          Prevention  and  Therapy/Tianjin’s  Clinical  Research  Center  for  Cancer,  Tianjin  300060,  China;2.  Dept.  of
          Pharmacy,  Tianjin  Cancer  Hospital  Airport  Hospital,  Tianjin  300308,  China;3.  College  of  Biotechnology,
          Tianjin University of Science & Technology, Tianjin 300457, China)

          ABSTRACT    OBJECTIVE  To investigate the effects of Mitoxantrone liposomes (Lipo-MIT) on the proliferation, migration and
          cancer  stem  cell (CSCs)  stemness  of  ovarian  cancer  cells,  as  well  as  to  explore  its  mechanism  of  action  based  on  the
          phosphoinositide  3-kinase (PI3K)/protein  kinase  B (AKT)  pathway.  METHODS  The  effects  of  Lipo-MIT  on  cell  proliferation,
          migration  and  the  stemness  characteristics  of  CSCs  were  investigated  through  in  vitro  experiments. A  human  ovarian  cancer A2780
          cells  xenograft  tumor  model  of  nude  mouse  was  established  to  explore  the  effects  of  Lipo-MIT  at  doses  of  2  and  5  mg/kg  on  the
          safety of tumor-bearing mice, as well as in vivo tumor growth and the pathological characteristics of tumor tissues. The influence of
          Lipo-MIT  on  the  expression  levels  of  PI3K/AKT  pathway-related  proteins,  epithelial-mesenchymal  transition  related  proteins,  and
          stemness  related  proteins  in  both  cells  and  tumor  tissues  was  also  investigated.  RESULTS  The  half  maximal  inhibitory
          concentrations  of  Lipo-MIT  against  A2780,  SK-OV3,  and  OV-CAR5  cells  were  0.72,  5.41,  and  2.77  μmol/L,  respectively.
          Compared  with  solvent  control (0.1%  dimethyl  sulfoxide),  0.5-2.5  μmol/L  Lipo-MIT  significantly  reduced  the  cell  colony
                                                              formation  rate,  shortened  the  cell  migration  distance,
              Δ 基金项目 中国医药卫生事业发展基金会医学科研项目(No.                  decreased  the  number  of  migrated  cells,  down-regulated  the
          HXHY2024KY0001);北京医学奖励基金会课题(No.YXJL-2022-0435-      protein  expression  of  N-cadherin,  up-regulated  the  protein
          0392);天津市医学重点学科建设项目(No.TJYXZDXK-3-003A)             expression  of  E-cadherin (P<0.05),  and  also  decreased  the
             *第一作者 副主任药师,硕士生导师,博士。研究方向:抗肿瘤药
                                                              stem  cell  sphere  formation  frequency  and  down-regulated  the
          物新机制。E-mail:lvn1314@126.com
              # 通信作者 教授,博士生导师,博士。研究方向:新药发现与作用                 protein   expression   of   aldehyde   dehydrogenase   1A1
          机制。E-mail:sunhua@tust.edu.cn                       (ALDH1A1) (P<0.05).  Additionally,  1.0  and  2.5  μmol/L


          · 42 ·    China Pharmacy  2026 Vol. 37  No. 1                                中国药房  2026年第37卷第1期
   43   44   45   46   47   48   49   50   51   52   53